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Age-related decline of serum T and its clinical impli-cations remain the subject of controversies. These
are unlikely to be settled soon due to the lack of appro-
priate randomized trials. It nevertheless is important to
keep adjusting clinical practice advice to current
knowledge.
Population means of serum T decline and SHBG in-
creaseswith age, but there is considerable between-subject
variation in prevalent (free) T in apparently healthy older
men (1, 2). Genetic and lifestyle-related factors account
for only part ofT variation (1),which suggests that health-
related factors contribute. Indeed, to define a “healthy
state” for populations of elderly men with a high preva-
lence of (subclinical) comorbidities is not straightforward.
Recently, serumTwas reported as stable across age strata
among men self-reporting very good health (3).
Signs and symptoms of “normal aging” are reminiscent
of those in young hypogonadal men (1, 4), which raised
expectations that T substitution in (borderline) low T
might help reverse or limit progression of some conse-
quences of aging, if not improve general health and lon-
gevity. In apparent support of the concept of late-onset
hypogonadism (LOH), observational studies have re-
ported associations of serum (free) T below the reference
for young men with symptoms that are part of the clinical
picture of hypogonadism, ie, in particular sexual symp-
tomsbesides others suchas fatigue, decreasedmusclemass
andphysical vigor, or osteopenia (1, 2, 4–8).According to
practice guidelines (4, 8), the diagnosis of androgen defi-
ciency in the elderly or LOH, for which T treatmentmight
be considered, should be based on the concurrent presence
of consistent symptoms of hypogonadism and unequivo-
cally low serum (free) T. However, symptoms and low T
both become more prevalent and less specific with age, so
that the likelihood of LOH diagnosis increases (5),
whereas a causal link between clinical and hormonal find-
ings becomesmore evasive. A close look at the data shows
that a majority of symptomatic men do not have low T,
whereas a substantial part of those with low T are asymp-
tomatic (5). Among men with LOH, clinicians thus have
limited ability to distinguish those in whom low T is the
cause of symptoms from those inwhom lowT is unrelated
to their health problem or rather its consequence. As an
epiphenomenonof comorbidity, lowTcanbe irrelevant to
the patient’s health state, or of clinical relevance by con-
tributing to further deterioration of health, or a beneficial
adaptive response to the present status (9).
Beyond classical symptoms of hypogonadism, low T
and LOH have been associated in observational studies
with prevalent and/or incident obesity, metabolic syn-
drome, type 2 diabetes, dyslipidemia, and other cardio-
vascular risk factors (10, 11). The relation between serum
T and metabolic disturbances is likely bidirectional, but a
major component of reverse causality is apparent from
effective restoration of serum T with lifestyle measures
andweight loss (10). Systematic review andmeta-analysis
of community-based observational studies indicate a
mostly modest association in elderly men of low endoge-
nous T with incident cardiovascular disease and risk of
cardiovascular and all-cause death. This might imply pro-
tective effects of T, but authors generally concur to con-
sider residual confounding with low T a marker of poor
health status as a plausible interpretation of the data (11–
13). Marked between-study heterogeneity, partly ac-
counted for by characteristics of the subjects and study
methods, tend to support the latter view (12). Yeap et al
(14) reported a U-shaped association between T (and cal-
culated free T) and all-cause mortality in older commu-
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nity-dwelling Australian men; whereas the highest mor-
tality was in the lowest T quartile, mortality was not
significantly lower in the highest quartile, although men
with midrange T had the lowest mortality. As for all ob-
servational studies, an effect of residual confounding can-
not be excluded, but if confirmed, these findings are com-
patible with neither a direct causal relation between T
deficiency and mortality nor interpretation of low T as a
simple biomarker of ill health.
In an attempt to improve specificity of the LOH diag-
nosis, Wu et al (6) proposed minimal diagnostic criteria,
derived from elegant cluster analysis of data from the Eu-
ropean Male Aging Study (EMAS) and consisting of the
“syndromic” simultaneous presence of three sexual symp-
toms (ie, poor morning erections, decreased sexual inter-
est, and erectile dysfunction), together with a serum total
T 11 nmol/L (320 ng/dL) and free T 220 pmol/L (6.4
ng/dL); men fulfilling these criteria with serum total T 
8 nmol/L (230 ng/dL) are considered as having severe
LOH (6, 7). Prevalence of such defined LOH in the EMAS
population increased with age, body mass index, and
number of coexisting illnesses and was 5.1% in men
70–79 years old (6). The men with LOH had a lower
hemoglobin, muscle- and bone mass and poorer physical
performance and general health compared to their peers;
men with low T only, irrespective of sexual symptoms,
showed lesser magnitude of associations with the same
end-points (7).
In this issue of the JCEM, Pye et al (15) report prospec-
tive data on mortality in 2599 community-dwelling men
fromEMAS, aged 40–79 years and followed for amedian
of 4.3 years. Global mortality was 5.7%, whereas mor-
talitywas 30.9% in 55menwith LOH.After adjusting for
age, center, current smoking, body mass index, and poor
general health, 29 men with severe LOH had a 5-fold risk
of all-cause mortality compared to men without LOH;
mortality was 2-fold in men with T  8 nmol/L (230
ng/dL) compared to eugonadalmen, irrespective of sexual
symptoms, andwas 3-fold higher inmenwith three sexual
symptoms compared to asymptomatic men, irrespective
of serum T. Risks were similar for cardiovascular death.
Although based on a small number of events, these obser-
vations fit expectations. Indeed, besides reports of asso-
ciation of low T with mortality, meta-analysis of 12 pro-
spective cohort studies involving 36 744 participants
confirmed individual reports of association of erectile dys-
function with increased risk of cardiovascular disease,
stroke, and all-cause mortality (16). Although possibly
independent of “classical” cardiovascular risk factors
(16), these associationsmost likely reflect commonpatho-
physiological mechanisms between erectile dysfunction
and cardiovascular disease and/or a role of erectile dys-
function as a marker of more generalized vascular alter-
ations. Anyway, sexual function and poor health do not
matchwell, and considering the relatively short follow-up
in EMAS, observed associations between sexual symp-
toms and mortality most likely reflected pre-existing car-
diovascular disease or more generalized health problems.
In this regard, two aspects of the EMAS findings in severe
LOH are noteworthy: first, no statistical interaction was
observed between associations of low T and sexual symp-
tomswithmortality; and second, a broadly similar pattern
was observed for cardiovascular- and cancer-relatedmor-
tality (15). The characteristics ofmenwith LOHreflecting
poorer general health status (7), the apparently indepen-
dent associations of low T and sexual symptoms with ad-
verse outcome, and the associationwithmultiple causes of
mortality all suggest that severe LOH is in essence a non-
specific marker of poor health and frailty in older men,
rather than revealing a causative role of low T in the de-
terioration of health and risk of death.
In any case, as concluded by the EMAS authors, severe
LOH identifies a small group of men at high risk of death
in need of medical attention. This raises the question
whether this should include considering T therapy. Pres-
ently, the risk-benefit profile of T therapy is not estab-
lished due to the lack of appropriate randomized trials
(11). Moreover, reported T trials are heterogeneous in
their inclusion criteria, going from healthy men with a
variety of baselineT levels tomenwith specific disease (eg,
liver cirrhosis, AIDS, type 2 diabetes, etc), and in their
treatment modalities. Applied dosages often were supra-
physiological, either manifestly (eg, many regimens with
injections of short-acting T esters) or more subtly with
regimens aiming at stable “midphysiological” levels for
the youngwithout taking into accountdiurnal variationof
T levels. If there is indeed a U-shaped relation between
serum T and mortality (14), that might explain inconsis-
tencies among study results. Review of the literature
shows that T treatments have not been proven to be ben-
eficial with respect to cardiovascular disease, but neither
have they definitely shown specific adverse cardiovascular
effects (11). It is nevertheless important to pay attention to
recent data suggesting that T treatment might carry a car-
diovascular risk. Xu et al (17) concluded from a meta-
analysis of placebo-controlled, randomized trials that ex-
ogenous T overall, but in particular in trials not funded by
industry, increased the risk of cardiovascular-related
events. Results should be interpreted with caution in view
of severe limitations of included studies. Basaria et al (18)
reported early termination of a randomized trial with
transdermal T in elderly men with low T, limitations in
mobility, and high prevalence of cardiovascular risk fac-
tors because of increased incidence of (diverse) cardiovas-
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cular-related adverse events. Shore et al (19) reported, in
anobservational study in1031veteranswith lowT(250
ng/dL), lowermortality in 398T-treatedmen compared to
untreatedmen. In contrast, Vigen et al (20) found, in 8709
men in the VA health care who underwent coronary an-
giography and had low T (300 ng/dL), that 1223 T-
treated men had a higher risk of adverse outcome (myo-
cardial infarction, stroke, death). These data, although
not conclusive, indicate the possibility that T treatment in
LOH carries a risk of cardiovascular-related adverse
events, and that frail elderly men and men with prevalent
cardiovascular disease might bemore at risk. These warn-
ings emphasize the appropriateness of a cautious, re-
strained approach to T treatment in elderly men while we
await more robust evidence from randomized trials. A
paradox hereby is that among elderly men meeting sug-
gested criteria for diagnosis of symptomatic androgen de-
ficiency or LOH (4, 6, 8), in the present state of knowledge
treatment should be discouraged in those most severely
affected because low T is less likely to substantially con-
tribute to their health problems and they might be at
higher risk of adverse treatment effects.
In conclusion, the finding of a severe LOH should be
taken by clinicians as a warning of a potentially high-risk
health status of their patient and should prompt them to
take appropriate action, which in the present state of the
art should not include T treatment.Whether screening for
severeLOHasamarker of poorhealthhas a role in clinical
practice has not been studied, but it seems highly unlikely
considering the low prevalence of severe LOH and clini-
cally obvious poor health in at least part of this small
number of subjects.
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